Sugi Predict

Sugi Predict / Compounds / SCHEMBL1043161

SCHEMBL1043161

SCHEMBL1043161

Oc1ccc2c(Cl)ccnc2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TLR8 Q9NR97 2/20 0.51
▸ MAPT P10636 6/20 0.47
▸ GAA P10253 3/20 0.47
▸ ATM Q13315 1/20 0.47
▸ MEN1 O00255 6/20 0.46
▸ KMT2A Q03164 6/20 0.46
▸ ALDH1A1 P00352 3/20 0.46
▸ CASP1 P29466 1/20 0.46
▸ CASP7 P55210 1/20 0.46
▸ NR4A2 P43354 1/20 0.43
▸ SOS2 Q07890 1/20 0.43
▸ TDP1 Q9NUW8 4/20 0.43
▸ MCL1 Q07820 2/20 0.43
▸ HSD17B10 Q99714 1/20 0.41
▸ TTR P02766 1/20 0.41
▸ ESR1 P03372 2/20 0.40
▸ ESR2 Q92731 2/20 0.40
▸ SMYD3 Q9H7B4 1/20 0.39
▸ ESRRB O95718 1/20 0.39
▸ ESRRA P11474 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29612575 1.00 TLR8 (0.51) TLR8MAPTGAAATMMEN1
Ammonia Solution, Strong SCHEMBL27616951 0.98 TLR8 (0.50) TLR8MAPTGAAATMMEN1
SCHEMBL29729491 0.84 ESR1 (0.50) TLR8MAPTGAAATMMEN1
SCHEMBL6162407 0.84 ESR1 (0.50) TLR8MAPTGAAATMMEN1
Bromide SCHEMBL9069911 0.82 ESR1 (0.49) TLR8MAPTGAAATMMEN1
SCHEMBL29396540 0.79 NR4A2 (0.66) TLR8MAPTGAAATMMEN1
SCHEMBL317202 0.79 NR4A2 (0.66) TLR8MAPTGAAATMMEN1
SCHEMBL29509132 0.79 TLR8 (0.54) TLR8MAPTGAAATMMEN1
SCHEMBL28164080 0.79 TLR8 (0.54) TLR8MAPTGAAATMMEN1
SCHEMBL22461265 0.78 TLR8 (0.50) TLR8MAPTGAAATMMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12595245-B2 Inhibitors of MET kinase CELYN THERAPEUTICS, INC. (US) 2026-04-07 — — US disclosed
US-20260070888-A1 7-ALKOXYQUINOLINES AS MODULATORS OF POLRMT PRETZEL THERAPEUTICS, INC. (US) 2026-03-12 — — US disclosed
US-12479826-B2 Pyridazinyl amino derivatives as ALK5 inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2025-11-25 — — US disclosed
US-12281079-B2 Quinoline derivatives, processes for their preparation and uses thereof for the treatment of cancer LEAD DISCOVERY CENTER GMBH (DE) 2025-04-22 — — US disclosed
CN-112028825-B Tyrosine kinase inhibitor and pharmaceutical composition containing same 广东众生睿创生物科技有限公司 2025-03-14 — — CN disclosed
CN-119306737-A Benzo heterocyclic compound, pharmaceutically acceptable salt or stereoisomer thereof, and preparation method and application thereof 江苏集萃分子工程研究院有限公司 2025-01-14 — — CN disclosed
US-20250011299-A1 PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2025-01-09 — — US disclosed
EP-3293177-B1 TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME GUANGDONG RAYNOVENT BIOTECH CO LTD (CN) 2024-11-27 — — EP disclosed
US-20240382474-A1 ENPP1 MODULATORS AND USES THEREOF VIR BIOTECHNOLOGY INC (US) 2024-11-21 — — US disclosed
EP-4448510-A1 INHIBITORS OF MET KINASE Kinnate Biopharma Inc. (US) 2024-10-23 — — EP disclosed
CN-1597667-A Quinazoline derivatives as angiogenesis inhibitors ASTRAZENECA AB (SE) 2005-03-23 — — CN disclosed
CN-1167422-C Quinazoline derivatives as angiogenesis inhibitors — 2004-09-22 — — CN disclosed
US-20040082780-A1 Vanilloid receptor ligands and their use in treatments AMGEN, INC. 2004-04-29 — — US disclosed
WO-2004014871-A1 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS AMGEN INC. (US) 2004-02-19 — — WO disclosed
CN-1346271-A Quinazoline derivatives as angiogenesis inhibitors ASTRAZENECA UK LTD (SE) 2002-04-24 — — CN disclosed
WO-2002000622-A2 AMINOALCOHOL DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-01-03 — — WO disclosed
EP-1154774-A1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS AstraZeneca AB (SE) 2001-11-21 — — EP disclosed
WO-2000047212-A1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS ASTRAZENECA AB (SE) 2000-08-17 — — WO disclosed
US-5773449-A BACTERICIDES FOR HELICOBACTER ZENYAKU KOGYO KABUSHIKI KAISHA (JP) 1998-06-30 — — US disclosed
EP-0786454-A1 THIOQUINOLONE DERIVATIVE ZENYAKU KOGYO KABUSHIKIKAISHA (JP) 1997-07-30 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240382474-A1 ENPP1 MODULATORS AND USES THEREOF ENPP1, ENPP2, ENPP3 TLR8 4788/4885MAPT 4656/4885GAA 1022/4885
US-12595245-B2 Inhibitors of MET kinase MET, ABL1, ERBB2 TLR8 2170/4885MAPT 2891/4885GAA 1837/4885
US-12281079-B2 Quinoline derivatives, processes for their preparation and uses thereof for the treatment of cancer AVPR2, AVPR1A, VHL TLR8 3993/4885MAPT 2941/4885GAA 939/4885
US-12479826-B2 Pyridazinyl amino derivatives as ALK5 inhibitors ALK, TGFBR1, ACVR1 TLR8 913/4885MAPT 2942/4885GAA 1552/4885
US-20250011299-A1 PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS ALK, TGFBR1, ACVR1 TLR8 913/4885MAPT 2942/4885GAA 1552/4885
US-20260070888-A1 7-ALKOXYQUINOLINES AS MODULATORS OF POLRMT POLRMT, MRM1, POLM TLR8 3841/4885MAPT 2925/4885GAA 2562/4885
US-20040082780-A1 Vanilloid receptor ligands and their use in treatments TRPV1, TRPV2, TRPV3 TLR8 313/4885MAPT 680/4885GAA 1135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.